Vertex’s Exa-Cel Off-Target Analyses Set Early Bar For Other Genome Editing Products

 
• By Sue Sutter
  
Foggy road
FDA's guidance is foggy on the quantum of evidence needed for nonclinical off-target analyses. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers